HER2-targeted therapy influences CTC status in metastatic breast cancer

PURPOSE: As an independent, negative-prognostic biomarker for progression-free survival (PFS) and overall survival (OS), circulating tumor cells (CTCs) constitute a promising component for developing a liquid biopsy for patients with metastatic breast cancer (MBC). The effects of HER2-targeted thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Deutsch, Thomas M., Riethdorf, Sabine, Fremd, Carlo, Feisst, Manuel, Nees, Juliane, Fischer, Chiara, Hartkopf, Andreas D., Pantel, Klaus, Trumpp, Andreas, Schütz, Florian, Schneeweiss, Andreas, Wallwiener, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274999/
https://www.ncbi.nlm.nih.gov/pubmed/32436146
http://dx.doi.org/10.1007/s10549-020-05687-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274999/
https://www.ncbi.nlm.nih.gov/pubmed/32436146
http://dx.doi.org/10.1007/s10549-020-05687-2

Ejemplares similares